AUSTRALIAN approved antidepressant drug trazodone, a selective serotonin reuptake inhibitor, has been found to have the ability in vitro and in vivo to reverse mouse-brain degenerative effects such as those in Alzheimer's Disease, other dementias, Parkinson's, multiple sclerosis and Huntington's.
The research out of UK centres, including the School of Pharmacy at the University of Nottingham, has now recommended clinical trial testing in patients, with the possibility of its availability for patients within two years, given that it is already approved for use in humans.
CLICK HERE to access the research.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Apr 17
